Inivata Publishes Results of Analytical Validation for InVisionFirst-Lung ctDNA Liquid Biopsy

2018, News

Publication support robustness and reproducibility of the InVision™ platform

Industry-leading sensitivity and specificity shown across all classes of genomic alterations relevant to non-small cell lung cancer

Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care, today announces the publication of the analytical validation of its InVisionFirst-Lung targeted advanced sequencing test. The results were published in PLoS ONE and build on previous development work on the InVision platform also recently published in PLoS ONE .

The InVisionFirst-Lung test is intended to aid clinicians in treatment decisions for non-small cell lung cancer (NSCLC), using targeted advanced sequencing technology to detect cancer genomic alterations in selected genes from circulating tumor DNA (ctDNA) isolated from plasma samples.

The test provides comprehensive genomic profiling from circulating tumor DNA, to identity actionable genomic alterations in genes commonly mutated in NSCLC and other cancer types. The assay has been developed to detect point mutations, indels, amplifications and gene fusions that commonly occur in NSCLC.

Given the low concentration of ctDNA relative to total cell-free DNA in circulation, detection of somatic mutations from ctDNA requires very high sensitivity to deliver clinical benefits to the broadest patient population. InVisionFirst-Lung was shown to demonstrate industry-leading sensitivity and specificity across all classes of genomic alterations relevant to NSCLC.

Michael Stocum, Chief Executive Officer of Inivata, said: “This ongoing rigorous validation showed the InVisionFirst-Lung assay to be highly sensitive, specific and robust, achieving the analytical requirements for the delivery of valuable clinical information to aid the treatment of lung cancer. We believe we have demonstrated levels of sensitivity and specificity beyond those published for other liquid biopsy platforms and which could bring significant benefits for clinical applications.”

Study Summary

• Study with almost 1,000 samples demonstrated exceptional limit of detection and high reproducibility for all types of clinically relevant somatic mutations
• 99.48% sensitivity for single nucleotide variants (SNVs) present at a variant allele fraction (VAF) range of 0.25%-0.33%
• 92.46% sensitivity for indels at 0.25% VAF and a high rate of detection at lower frequencies while retaining high specificity (99.9997% per base)
• For VAFs as low as 0.06-0.08%, more than half of SNVs were detected
ALK and ROS1 gene fusions also detected, as well as DNA amplifications in ERBB2, FGFR1, MET and EGFR with high sensitivity and specificity
ALK and ROS1 fusions were detected down to 0.06% VAF demonstrating the ability to detect rare genomic alterations at very low but clinically meaningful allele frequencies
• Comparison between the InVisionFirst-Lung test and a select group of single analyte assays using digital PCR (dPCR) showed high concordance with a positive agreement of 100%


About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to Follow us on Twitter @Inivata.


Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US) +44 (0)20 3709 5700, +1 516 503 0271


Karen Chandler-Smith +44 (0)7900 430235


Our Technology

Our Solutions

Latest News